Trial Profile

Safety Study of Tivanisiran to Treat Dry Eye

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tivanisiran (Primary)
Indications Dry eyes
Focus Adverse reactions; Registrational
Acronyms FYDES
Sponsors Sylentis

Most Recent Events

16 Feb 2024 Status changed from active, no longer recruiting to completed.
18 Dec 2023 According to a Sylentis Media Release, at upcoming medical meetings additional data and analyses will be submitted for presentation.
18 Dec 2023 According to a Sylentis Media Release, this trial achieved the primary endpoint of the study by demonstrating the long-term safety of tivanisiran ophthalmic solution administration. 301 patients with dry eye disease recruited from 26 centers in the United States participated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com